The detection of promoter region hypermethylation and transcriptional silencing has facilitated the identification of candidate renal cell carcinoma (RCC) tumour suppressor genes (TSGs). We have used a genome-wide strategy (methylated DNA immunoprecipitation (MeDIP) and whole-genome array analysis in combination with highdensity expression array analysis) to identify genes that are frequently methylated and silenced in RCC. MeDIP analysis on 9 RCC tumours and 3 non-malignant normal kidney tissue samples was performed, and an initial shortlist of 56 candidate genes that were methylated by array analysis was further investigated; 9 genes were confirmed to show frequent promoter region methylation in primary RCC tumour samples (KLHL35 (39%), QPCT (19%), SCUBE3 (19%), ZSCAN18 (32%), CCDC8 (35%), FBN2 (34%), ATP5G2 (36%), PCDH8 (58%) and CORO6 (22%)). RNAi knockdown for KLHL35, QPCT, SCUBE3, ZSCAN18, CCDC8 and FBN2 resulted in an anchorage-independent growth advantage. Tumour methylation of SCUBE3 was associated with a significantly increased risk of cancer death or relapse (P ¼ 0.0046). The identification of candidate epigenetically inactivated RCC TSGs provides new insights into renal tumourigenesis.
Introduction
Erroneous hypermethylation of CpG islands associated with gene promoters induces transcriptional silencing by multiple mechanisms involved in chromatin modification (Li et al., 2007) . Since the identification of RB1 tumour suppressor gene (TSG) inactivation by promoter hypermethylation 17 years ago (Ohtani-Fujita et al., 1993) , it has become increasingly apparent that tumour suppressor promoter methylation has a significant role in the clonal evolution of cancer. For renal cell carcinoma (RCC), large-scale sequencing projects have revealed that, with the exception of VHL TSG, candidate TSGs are mutated in o10% of tumours (Dalgliesh et al., 2010) , whereas a much larger number of TSGs are frequently silenced by cancer-specific promoter methylation. Indeed, several important RCC TSGs are frequently inactivated by promoter hypermethylation but rarely mutated; these include RASSF1A (Morrissey et al., 2001; Hogg et al., 2002 , Morris et al., 2003 , SFRP1 (Dahl et al., 2007; Morris et al., 2010) , DAPK1 (Morris et al., 2003; Christoph et al., 2006) and SPINT2 (Morris et al., 2005) . These observations, in combination with the frequent difficulty of distinguishing 'driver' and 'passenger' mutations in human cancers, suggest that strategies to identify genes targeted by de novo promoter methylation can provide an efficient approach to identify novel RCC TSGS.
In the past decade, the tools available to those wishing to identify epigenetically silenced genes in cancer have developed rapidly. Initially, significant progress was made by functional epigenomic approaches using gene expression microarrays to study changes in gene expression following global demethylation of cancer cell line genomes (Yamashita et al., 2002; Sato et al., 2003; Lodygin et al., 2005) . For RCC, this approach resulted in the identification of B14 candidate RCC TSGs (Morris et al., 2005 (Morris et al., , 2010 Ibanez de Caceres et al., 2006) . However, the application of this strategy is limited, as evidenced by the observation that many of the genes that are upregulated in RCC cell lines do not show promoter methylation and that many genes that are methylated in cell lines are not methylated in primary tumours (Morris et al., , 2010 . The technique of methylated DNA immunoprecipitation (MeDIP) enables the isolation of the methylated DNA fraction from primary tumour DNA, which can then be analysed by high-density whole-genome microarray, thus allowing the direct analysis of genomic methylation patterns in primary tumours. Previously, no wholegenome methylation detection strategies were applied to the analysis of methylation in RCC. We have used MeDIP with comparative high-density whole-genome microarray analysis to identify differentially methylated regions in primary tumour DNA directly. We have combined these data with expression array data from RCC-derived cell lines that have been globally demethylated by treatment with 5-Aza-2 0 -deoxycytidine to increase the likelihood of identifying tumour-specific methylation that correlates to gene silencing. We have identified a number of genes that are frequently methylated in an RCC tumour-specific manner resulting in gene silencing. We have also identified a subset of these genes that have shown in vitro tumour suppressor activity.
Results
Identification of candidate silenced genes involved in RCC DNA samples from nine clear cell RCC tumours and from three non-malignant kidneys were prepared by MeDIP, and the resulting methylated and unmethylated fractions were hybridised to Nimblegen HG18 wholegenome oligonucleotide arrays. Each gene is represented on the HG18 arrays by up to 14 probes grouped into 'peaks'. A 'peak score' of 2 equals a twofold enrichment of DNA in the methylation immunoprecipitation fraction. A twofold enrichment is the minimum level of methylation that we have accepted to merit further investigation.
To prioritise the identification of gene promoters that were frequently methylated in RCC tumours, we created a shortlist using the following criteria; there must be no methylation in any of the three non-malignant kidney samples, and at least 45% (4/9) of RCC tumours must have a peak score of X2. Applying these criteria gave a shortlist of 574 'peaks', which related to 443 individual genes and open reading frames (Supplementary Table 2 shows a full list of genes that had peak scores in 4/9 primary tumours).
To reduce the list of genes to those in which promoter methylation is likely to be biologically relevant, we applied a further filter. We have previously analysed genome-wide expression changes in 11 RCC-derived cell lines following treatment with the demethylating agent 5-Aza-2 0 -deoxycytidine using Affymetrix U133 Plus-2 microarrays (Morris et al., 2010) . We prioritised those genes from our MeDIP methylation array that also showed a significant reexpression (X8-fold change, see Morris et al. (2008) ) in at least two cell lines. A total of 78 genes met this criteria, including two, KRT19 and EDNRB, previously shown to be epigenetically silenced in RCC (Pflug et al., 2007; Morris et al., 2008) and two, RARRES1 and IRF7, that have been shown to be infrequently methylated in RCC .
Eleven candidate genes were not analysed further, as they had no CpG island at the predicted promoter region (from www.genome.ucsc.edu and Genomatix promoter inspector (www.genomatix.de)). X-chromosome and imprinted genes were also excluded (n ¼ 8), leaving 55 genes that have not previously been associated with epigenetic dysregulation in RCC as candidates for further analysis (see Figure 1 for a schematic of filtering criteria and Table 1 for a full list of candidate genes).
Validation of methylation in candidate genes PCR primers were designed to amplify the predicted promoter region for all 55 candidate genes from bisulphite-modified DNA (see Supplementary Table 1 for primer details). Direct sequencing of promoter regions from nine RCC cell lines and six normal kidney samples obtained from non-RCC patients was performed to confirm the results from the MeDIP analysis. Genes were selected for further investigation if methylation was present in X40% of cell lines and was absent in all 6 non-malignant kidney samples, as determined by sequencing and combined bisulphite and restriction 
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Up-regulated >8fold In 2 or more lines >2000 targets Figure 1 Schematic of method applied to shortlist candidate genes. Genes identified as methylated in primary RCC tumours and not in normal kidney DNA were compared with the differential expression of those genes in RCC-derived cell lines following culture in the demethylating agent 5-Aza-2 0 -deoxycytidine. Those genes that were determined methylated by MeDIP array and reexpressed in at least two cell lines were considered for further analysis (see main text for further details). Promoter hypermethylation in primary RCC tumours To determine whether the 33 candidate genes methylated in RCC cell lines were methylated in primary tumours, we performed CoBRA analysis in a further 6 normal kidney samples from patients with no history of RCC, as well as in 60 primary RCCs and 18 normal kidney samples matched to 18 primary RCCs. PKHD1L1, although frequently methylated in primary RCC (50%), was also found to be methylated in 2/6 additional normal kidney samples (2/12 normal kidney samples tested) and was excluded from further investigation.
A two-stage protocol was used to determine methylation frequency in primary RCC. Initially, 20 primary RCC tumours were analysed; if the frequency of methylation was 415%, a further 40 RCCs were tested. Of the 33 genes analysed, 21 were not (CLDN1, DGKI, ALDH2, CACNB2, HTR1A, SLC29A4, NRARP, RHOD and PRRX2) or were infrequently (p15% of tumours; BIK, HMX1, ANK3, ALOX15, LYNX1, DUOX2, PROM1, CELSR3, P2RX5, LRRC2, SLC6A2 and TF) methylated. No further analysis was carried out on these genes. Twelve gene promoters were methylated in 415% of the first 20 tumours analysed; however, after testing a further 40 RCCs, two genes (IGFBP2 and EGR4) were methylated in o3% (1/40 tumours) of the additional samples and were not further investigated.
Nine gene promoters were frequently methylated (415%); these were ATP5G2 (36% of tumours methylated), PCDH8 (58% of tumours methylated), CORO6 (22% of tumours methylated), KLHL35 (39% of tumours methylated), QPCT (19% of tumours methylated), SCUBE3 (19% of tumours methylated), ZSCAN18 (32% of tumours methylated), CCDC8 (35% of tumours methylated) and FBN2 (34% of tumours methylated). These gene promoters were not methylated in any non-tumour kidney samples resected from regions adjacent to the tumours (n ¼ 18). The PTPLAD2 CpG island was methylated in 37% of primary tumours. However, methylation was also observed in 4/18 kidney samples restricted adjacent to the methylated tumours. Figure 2 shows representative CoBRA digest products.
To analyse the methylation status of the nine genes that are frequently methylated in an RCC tumourspecific manner in more detail, we carried out bisulphite sequencing in tumours that had been identified as methylated by CoBRA (n ¼ 8 tumours per gene). The mean methylation index (MI) for the genes analysed by sequencing ranged from 25 to 59% (SCUBE3, MI ¼ 25%; ZSCAN18, MI¼ 43%; CORO6, MI¼ 31%; FBN2, MI ¼ 31%; ATP5G2, MI¼ 59%; QPCT, MI¼ 34%; CCDC8, MI ¼ 52%; KLHL35, MI ¼ 39%; and PCDH8, MI ¼ 44%). (Figure 3 ). Of the genes identified by this screen, only one, DGKI, has been shown to be mutated in RCC; this was in 1 tumour case out of 101 analysed (Dalgliesh et al., 2010) .
Expression analysis of identified genes
Reverse transcriptase-PCR analysis of 22 pairs of tumours and corresponding non-tumour kidney complementary DNA confirmed that the genes identified by our screen were frequently silenced or downregulated. Transcripts were present in all tumour-matched normal kidney tissues and absent or significantly reduced (45-fold reduction compared with the corresponding normal sample) in many tumour samples: FBN2 (expression absent/reduced) in 55% of the 22 RCCs, ATP5G2 (41%), KLHL35 (41%), PCDH8 (36%), CCDC8 (23%), QPCT (41%), SCUBE3 (45%), ZSCAN18 (23%) and CORO6 (41%). Tumours with absent/reduced expression were tested for gene methylation; for FBN2, ATP5G2, KLHL35, PCDH8 and CCDC8, most tumours tested demonstrated methylation (67, 77, 67, 88 and 80%, respectively; Figure 4a ). To further demonstrate that the presence of hypermethylated CpG islands was associated with the absence of each respective mRNA transcript, we carried out reverse transcriptase-PCR on methylated cell lines. Treatment with the demethylating agent 5-Aza-2 0 -deoxycytidine (5 mM) for 5 days restored gene expression (Figure 4b ). Functional analysis of the tumour suppressor activity of epigenetically inactivated genes To investigate whether the promoter region methylation and transcriptional silencing might promote tumourigenesis, RNAi was used to knock down the expression of the nine methylated genes in HEK293 cells. At 24 h after RNAi transfection, cells were seeded into 3% agar and colonies 4200 mm were counted after 21 days. Transcript knockdown was determined by reverse transcriptase-PCR and western blotting, where appropriate antibodies were available (Supplementary Figure 1) . Figure 5 ). All experiments were carried out independently in triplicate.
Analysis of promoter methylation and patient survival/ relapse Kaplan-Meier analyses revealed no significant associations between the risk of cancer death/relapse and tumour methylation status for ATP5G2 (P ¼ 0.5072),
QPCT (P ¼ 0.2982) and ZSCAN (P ¼ 0.5541). However, methylation of SCUBE3 was associated with a significantly increased risk of death (P ¼ 0.009) and cancer death or relapse (P ¼ 0.0046) ( Figure 6 ).
Discussion
Previously, we and others had used functional epigenomic screens to identify epigenetically inactivated TSGs in RCC (Morris et al., 2005 Ibanez de Caceres et al., 2006) . In contrast to high-throughput sequencing studies to detect genes mutated in RCC (Dalgliesh et al., 2010) , epigenetic studies have identified at least 18 genes that are inactivated in 420% of RCCs (Morris et al., 2010 and references within), including SPINT2 (Morris et al., 2005) , BNC1, CST6, PDLIM4, COL14A1 and COL15A1 (Morris et al., 2010) . However, to facilitate the identification of further RCC TSGs, we have used an approach that combined MeDIP with comparative high-density whole-genome microarray analysis and functional epigenomic expression data from RCC-derived cell lines treated with the demethylating agent 5-Aza-2 0 -deoxycytidine. Although this strategy also required a sequential prioritisation and analysis of genes to exclude those that were not frequently methylated in primary RCC, we were able to identify a further six genes that demonstrate promoter methylation in 430% of RCCs and three genes that had promoter methylation in X19% of RCCs. We note that several genes (for example, SFRP1 (Dahl et al., 2007; Morris et al., 2010) , DAPK1 (Morris et al., 2003; Christoph et al., 2006) and SPINT2 (Morris et al., 2005) ) that we and others have previously reported to be methylated in RCC were not identified by this strategy. This is likely to result from the promoter regions of these genes not being well covered by the HG18 Ct BstU1
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Un-meth.T. Methylated Tumors Figure 2 Representative CoBRA digests. Sixty sporadic RCC tumours were analysed for promoter methylation. Nine genes were frequently methylated: ATP5G2 (36%), PCDH8 (58%), CORO6 (22%), KLHL35 (39%), QPCT (19%), SCUBE3 (19%), ZSCAN18 (32%) CCDC8 (35%) and FBN2 (29%). The left panel is representative of tumours that were not methylated (un-meth T.), the other panels are representative of tumours that were methylated as determined by bisulphite-PCR product digestion with BstU1 (ct ¼ PCR product, BSTU1 ¼ PCR product digested with BSTU1).
methylation array and so suggests that further studies using higher-density arrays (or more-sensitive technologies) would lead to the identification of additional novel epigenetically regulated genes. Knockdown of six of these genes was also shown to increase anchorageindependent cell growth, providing direct functional evidence of tumour suppressor activity. The HEK293 cell line was used as an experimental model for the tumourigenicity assays, as all the target genes were expressed in this cell line (derived from Ad5-transformed embryonic kidney cells), and so the effect of each of the specific gene knockdowns could be evaluated in a consistent renal-derived cellular context. None of the nine genes have been previously reported to be methylated in RCC and, to the best of our knowledge, CCDC8, ATP5G2, KLHL35, CORO6, ZSCAN18 and SCUBE3 have not been previously reported to be methylated in neoplasia. FBN2 has recently been reported to be epigenetically silenced in colorectal, oesophageal and non-small-cell lung cancers (Chen et al., 2005; Tsunoda et al., 2009; Yagi et al., 2010) . QPCT, which encodes a glutaminyl cyclase (Fischer and Spiess, 1987; Pohl et al., 1991) , is frequently methylated in malignant melanoma (Muthusamy et al., 2006) . Functional PCDH8 is frequently lost in breast cancer through both mutation and promoter methylation (Yu al., 2008) , and also methylated in mantle cell lymphoma (Leshchenko et al., 2010) . FBN2 and the related gene FBN1 encode large modular extracellular matrix glycoproteins, which are the key components of human microfibrils (Zhang et al., 1994) . The microfibrillopathies, Marfan's syndrome and congenital contractural arachnodactyly, result from dominant mutations in FBN1 and FBN2, respectively (Robinson and Godfrey, 2000) . There is increasing evidence that these molecules regulate TGF-b signalling. The binding of TGF-b-bound large latency complex to fibrillins has two roles; it renders TGF-b inactive, facilitating fine control of TGF-b activity. It also concentrates TGF-b to specific locations, thus regulating the biological response to TGF-b (Annes et al., 2003) . FBN1 mutations in Marfan's syndrome result in the excess activation of TGF-b (Chaudhry et al., 2007) . However, less is known about the role of Fibrillin-2. Loss of Fibrillin-2 in RCC may contribute to a malignant phenotype by contributing to the dysregulation of the complex network of signalling pathways regulated by TGF-b. Loss of large extracellular matrix proteins may also give angiogenic and metastatic advantages to RCC. There is increasing evidence that protocadherins can function as tumour suppressors. Protocadherins 10 and 20 are epigenetically silenced in nasopharyngeal and lung cancers (Imoto et al., 2006; Ying et al., 2006) , and recently it has been reported that PCDH8 is methylated in mantle cell lymphoma and breast cancer (Yu et al., 2008; Leshchenko et al., 2010) . Yu et al. found that reexpressing wild-type PCDH8 in a breast cancer cell line inhibited cell migration. Although we did not find that silencing of PCDH8 increased the anchorageindependent growth potential of kidney cells, the role of protocadherins, and their mechanism of action, in renal tumourigenesis is likely to merit further investigation.
QPCT encodes a glutaminyl cyclase that converts precursor glutaminyl peptides to their bioactive pyroglutaminyl peptide forms (Fischer and Spiess, 1987; Pohl et al., 1991) . Loss of expression of members of this family of proteins has been observed in a number of tumour types, including QPCT itself in melanoma (Muthusamy et al., 2006) and phaeochromocytomas (Thoue¨nnon et al., 2007) . SCUBE (Signal peptide CUB EGF-like domain-containing protein) genes encode a small group of secreted plasma membrane-associated proteins characterised by an N-terminal signal peptide sequence, multiple EGF (epidermal growth factor) domains, a large spacer region containing multiple N-linked glycosylation sites and a C-terminal CUB (Complement subcomponent C1r/C1s EGF-related sea Urchin protein, Bone morphogenetic protein1) domain (Grimmond et al., 2000) . Little is known about SCUBE3; however, it is plausible to suggest that it may have an antitumourigenic role, in a similar manner to proteins such as gremlin (Morris et al., 2010) , in maintaining correct TGFb signalling. In addition, we note that methylation of SCUBE3 was associated with a significantly increased risk of cancer death/relapse.
The identification of frequent methylation of ATP5G2, which encodes a mitochondrial ATP synthase subunit C (Dyer and Walker, 1993) , in sporadic RCC is of interest as it is becoming increasingly apparent that mitochondrial dysregulation may have a significant role in the pathology of a number of tumour types, including RCC. Two common characteristics of tumours can both be related to errors in normal mitochondrial function. These are an increase in cellular energy production and the introduction of reactive oxygen species into the cellular environment, which, in turn, can induce a hypoxic response (for a review see Hu¨ttemann et al. (2008) ). Other genes encoding metabolic processes such as the succinate dehydrogenases (SDH) and fumarate hydratase (FH) have previously been shown to be inactivated in familial RCC (Morris et al., 2003 (Morris et al., , 2004 Ricketts et al., 2008) .
Very little is known about the function of the CORO6 gene product (coronin-6), but the other members of the coronin family are actin-binding proteins that have been shown to function in cell motility, vesicle trafficking and cell division (Roadcap et al., 2008) . Whether CORO6 has similar activity is unclear, but such fundamental cell functions are often dysregulated in cancer. Similarly, the function of KLHL35, CCDC8 and ZSCAN18 gene products is not well characterised, but we note that RNAi-induced downregulation of these transcripts resulted in some of the most significant growth advantages we observed in the anchorage-independent growth assay (to our knowledge there are no previous reports of a growth advantage to a non-cancer cell line following the knockdown of these genes and also of SCUBE3, QPCT and FBN2). These genes merit further investigation to determine their role in RCC. It will also be of interest to determine whether these genes are dysregulated in a broader range of tumours.
More than 200 000 new cases of kidney cancer are diagnosed in the world each year (Bray et al., 2002) , and 
*** ** ** ** *** ** Figure 5 Knockdown of expression of FBN2, CCDC8, ZSCAN18, SCUBE3, QPCT or KLHL35 increases anchorageindependent growth potential. An RNAi-induced reduced expression of FBN2, CCDC8, ZSCAN18, SCUBE3, QPCT or KLHL35 in HEK293 cells resulted in the growth of significantly more colonies 4200 mm in diameter compared with cells transfected with a control RNAi oligo when seeded at the same density into soft agar (**Po0.01, ***Po0.001). Each gene knockdown experiment was repeated three times. although, if detected early, partial or radical nephrectomy is an effective treatment, many patients present with advanced disease. The response of metastatic RCC to conventional chemotherapy is poor, but characterisation of the molecular pathology of RCC can provide a basis for developing novel therapeutic approaches. This is exemplified by the VHL TSG paradigm in which (a) inactivation of VHL is the most common event in sporadic clear cell RCC (Latif et al., 1993; Foster et al., 1994; Herman et al., 1994; Clifford et al., 1998) ; (b) VHL inactivation leads to stabilisation of HIF-1 and HIF-2 transcription factors and activation of hypoxic response genes that drive renal tumourigenesis (Maxwell et al., 1999) ; and (c) inhibitors (for example, tyrosine kinase inhibitors such as sorafenib and sunitinib) of HIF target pathways are active in the treatment of metastatic RCC (Chowdhury et al., 2008) . Hence, identification of frequently inactivated RCC TSGs can provide a basis for novel therapeutic interventions. Strategies to identify epigenetically inactivated TSGs therefore represent an important approach to elucidating the molecular pathogenesis of RCC and, furthermore, the detection of methylated RCC TSG DNA in urine or serum might be used as biomarkers for the diagnosis, staging or risk stratification of RCC (Battagli et al., 2003; Hoque et al., 2006; Urakami et al., 2006) . Although confirmation is required, our findings suggest that SCUBE3 methylation status could be a prognostic marker in RCC. Previous RCC epigenetic studies (Breault et al., 2005; Morris et al., 2005 Morris et al., , 2010 Christoph et al., 2006; Ibanez de Caceres et al., 2006; Yamada et al., 2006; Costa and Drabkin, 2007; McRonald et al., 2009) have identified candidate RCC TSGs that have functional roles in key pathways commonly dysregulated in cancer biology. Interestingly, many of the genes identified in this study, which were shown to be frequently methylated or to have in vitro growth suppressor activity, would not have been chosen as obvious candidate genes (none were represented in the 3544 genes sequenced in RCC by Dalgliesh et al. (2010) ). One advantage of unbiased genome-wide approaches, such as that used in this study, is the potential to uncover novel genes and pathways that can be targeted for further investigation.
Materials and methods
Patients and samples DNA from up to 69 primary RCCs (B80% clear cell, 20% non-clear cell) and matched adjacent macroscopically normal renal tissue and normal renal tissue from six patients undergoing non-cancer renal surgery (mean age 57 years, range from 23 to 79 years) were analysed. Nine tumour DNAs were used for MeDIP array analysis. Twenty tumour DNA samples were used to confirm initial array results and a further 40 were used to follow-up positive candidate genes (total ¼ 69). Local research ethics committees approved the collection of samples and informed consent was obtained from each patient. This study was conducted according to the principles expressed in the Declaration of Helsinki.
Cell lines, 5-Aza-2 0 -deoxycytidine treatment and microarray analysis RCC cell lines KTCL26, RCC4, UMRC2, UMRC3, SKRC18, SKRC39, SKRC45, SKRC47, SKRC54, 786-O, Caki-1, CAL54, RCC48, RCC1, RCC12, Caki-2, A498, ACHN and 769-P were routinely maintained in DMEM (Invitrogen, San Diego, CA, USA) supplemented with 10% FCS at 37 1C in 5% CO 2 . The demethylating agent 5-Aza-2 0 -deoxycytidine (Sigma-Aldrich, Dorset, UK) was freshly prepared in dd H 2 O and filter sterilised. Cell lines were plated in 75-cm 2 flasks in DMEM medium supplemented with 10% FCS at differing densities, depending on their doubling time, to ensure that both control and 5-Aza-2 0 -deoxycytidine-treated lines reached B75% confluency at the point of RNA extraction. After 24 h, cells were treated with 5 mM 5-Aza-2 0 -deoxycytidine. The medium was changed 24 h after treatment and then changed again after 72 h. RNA was prepared 5 days after treatment using RNABee (AMS Biotechnology, Oxford, UK). Total RNA from all 19 cell lines þ /À 5-Aza-2 0 -deoxycytidine was isolated using RNA-Bee reagent following the manufacturer's instructions (AMS Bio), followed by purification using RNeasy Minicolumns (Qiagen, Crawle, UK). Complementary RNA probes from KTCL26, RCC4, UMRC2, UMRC3, SKRC18, SKRC39, SKRC45, SKRC47, SKRC54, 786-O and Caki-1 cell lines were prepared using the Affymetrix protocol and hybridised to HG-U133 plus2 GeneChip oligonucleotide arrays (Affymetrix, Santa Clara, CA, USA). Array hybridisation and data production were carried out by the CRUK Paterson Institute Microarray Service (http://bioinformatics.picr.man.ac.uk/mbcf/). Complementary RNA probes for CAL54, RCC48, RCC1, RCC12, Caki-2, A498, ACHN and 769-P lines were prepared using the Illumina method and hybridised to Human WG-6 geneChip arrays (Illumina, Little Chesterford, UK).
MeDIP DNA preparation and analysis MeDIP was performed as per the suggested protocol of Nimblegen (Roch-Nimblegen, Madison, WI, USA). RNA-free genomic DNA was extracted from RCC cell lines and tumours by standard methods. A measure of 6 mg of each DNA sample was digested overnight at 37 1C with 24 U of MseI (supplemented with 100 ng/ml BSA). The reactions were stopped by heating at 65 1C for 20 min, and the success of the reactions was verified by running a small aliquot of the digested DNA on an agarose gel. DNA was quantified using a NanoDrop spectrophotometer (Thermo Scientific, Wilmington, DE, USA), and 1.25 mg of DNA was diluted in TE buffer to a final volume of 300 ml. The DNA was denatured at 95 1C for 10 min and 60 ml (250 ng) was removed for use as control (input) DNA. A volume of 60 ml of 5xIP buffer (100 mM Na phosphate pH7.0, 5 M NaCl, 10% Triton X-100) and 1 mg of IP antibody (mouse monoclonal anti-5-methylcytidine, Eurogentec, Southampton, UK) were added to the remaining DNA, and the mixture was incubated overnight at 4 1C with gentle rotation. Protein A agarose beads (24 ml) were prewashed twice in PBS/0.1% BSA, and resuspended in 24 ml 1xIP buffer; this 50% slurry was added to the DNA/antibody mixture and incubated for 2 h at 4 1C with gentle rotation. The beads were washed three times with 1xIP buffer and resuspended in 250 ml digestion buffer (1 M Tris-HCl pH 8.0, 0.5 M EDTA, 10% SDS; filter sterilised). A volume of 7 ml of proteinase K (at 10 mg per ml) was added to the above mixture, and incubation was carried out overnight at 55 1C. DNA was purified by phenol/chloroform extraction and ethanol precipitation (the latter with the addition of 20 mg glycogen to facilitate visualisation of the DNA pellet). A volume of 10 ng of input DNA and 10 ng of IP DNA were subjected to whole-genome amplification with the WGA2 kit (Sigma), and purified using the Qiaquick PCR purification kit (Qiagen). A measure of 4 mg of input and IP DNA was sent to Nimblegen Laboratories, differentially labelled and applied to the HG18 RefSeq Human Promoter Array. Bisulphite modification A volume of 0.5-1.0 mg of genomic DNA was denatured in 0.3 M NaOH for 15 min at 37 1C, and then unmethylated cytosine residues were sulphonated by incubation in 3.12 M sodium bisulphite (pH 5.0; Sigma)/5 mM hydroquinone (Sigma) in a thermocycler (Thermo-Hybaid, Ashford, UK) for 20 cycles of 30 s at 99 1C and 15 min at 50 1C. The sulphonated DNA was recovered using the Wizard DNA cleanup system (Promega, Madison, WI, USA) in accordance with the manufacturer's instructions. The conversion reaction was completed by desulphonating in 0.3 M NaOH for 10 min at room temperature. The DNA was ethanol-precipitated and resuspended in water.
RT-PCR conditions
Promoter methylation analysis CpG islands were identified on the human genome browser and putative promoter regions were predicted by Promoter Inspector software (Genomatix, Munich, Germany). Primers used to amplify these regions from bisulphite-modified DNA can be found in Supplementary Table 1 . Promoter region methylation in cell lines was identified by direct sequencing of bisulphite-PCR products as described previously (Morris et al., 2005) . CoBRA was carried out by digesting bisulphite-PCR products with BstU1. Promoter methylation analysis of tumour DNA was carried out by cloning bisulphite-PCR products into pGEM (Promega), followed by sequencing of individual clones using primers to T7 or M13.
Anchorage-independent growth assay RNAi 'silencer select' oligos against KLHL35 (s49143), FBN2 (s5049), ATP5G2 (s1781), SOX14 (s15948), CORO6 (s39713), CCDC8 (s228331), PCDH8 (s10114), SCUBE3 (s48237), ZSCAN18 (s35299) and QPCT (s24500) or 'Silencer select' control oligo no. 1 (Ambion, Austin, TX, USA) was transfected into HEK293 cells using Interferin reagent (Polyplus, Illkirch, France) following the manufacturer's instructions. After 24 h incubation, cells were seeded into 2 ml DMEM in 10% FCS and 3% agar. Cells were maintained by addition of 200 ml of DMEM in 10% FCS weekly. After 3 weeks of growth, a final count of colonies was performed. Cells not seeded into agar were incubated for a further 24 h before efficiency of knockdown was assessed by reverse transcriptase-PCR and western blotting (Supplementary Figure 1) .
Statistical analysis
Statistical analysis was performed as indicated with a significance level of 5%.
